Patents by Inventor Helle H. Petersen

Helle H. Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
    Patent number: 10717784
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 21, 2020
    Assignee: NOVO NORDISK A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR
    Publication number: 20180208675
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Application
    Filed: January 9, 2018
    Publication date: July 26, 2018
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
    Patent number: 9896513
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
  • ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR
    Publication number: 20160032012
    Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen